DK0830141T3 - Forbedrede virusvacciner - Google Patents
Forbedrede virusvaccinerInfo
- Publication number
- DK0830141T3 DK0830141T3 DK96913234T DK96913234T DK0830141T3 DK 0830141 T3 DK0830141 T3 DK 0830141T3 DK 96913234 T DK96913234 T DK 96913234T DK 96913234 T DK96913234 T DK 96913234T DK 0830141 T3 DK0830141 T3 DK 0830141T3
- Authority
- DK
- Denmark
- Prior art keywords
- virus
- strains
- inactivated
- neuraminidase
- hemagglutinin
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 11
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 108010006232 Neuraminidase Proteins 0.000 abstract 3
- 102000005348 Neuraminidase Human genes 0.000 abstract 3
- 239000000185 hemagglutinin Substances 0.000 abstract 3
- 101710091045 Envelope protein Proteins 0.000 abstract 2
- 101710154606 Hemagglutinin Proteins 0.000 abstract 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 2
- 101710176177 Protein A56 Proteins 0.000 abstract 2
- 101710188315 Protein X Proteins 0.000 abstract 2
- 102100021696 Syncytin-1 Human genes 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 229960003971 influenza vaccine Drugs 0.000 abstract 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 abstract 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 abstract 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- 241000712079 Measles morbillivirus Species 0.000 abstract 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 abstract 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/430,971 US5976552A (en) | 1995-04-28 | 1995-04-28 | Virus vaccines |
| PCT/US1996/005904 WO1996033738A1 (en) | 1995-04-28 | 1996-04-26 | Improved virus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0830141T3 true DK0830141T3 (da) | 2003-10-20 |
Family
ID=23709884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96913234T DK0830141T3 (da) | 1995-04-28 | 1996-04-26 | Forbedrede virusvacciner |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5976552A (da) |
| EP (1) | EP0830141B1 (da) |
| CN (1) | CN1141977C (da) |
| AT (1) | ATE243530T1 (da) |
| AU (1) | AU696690B2 (da) |
| CA (1) | CA2222283C (da) |
| DE (1) | DE69628834T2 (da) |
| DK (1) | DK0830141T3 (da) |
| ES (1) | ES2201184T3 (da) |
| PT (1) | PT830141E (da) |
| WO (1) | WO1996033738A1 (da) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485729B1 (en) * | 1993-09-13 | 2002-11-26 | Protein Sciences Corporation | Neuraminidase-supplemented compositions |
| AU745335B2 (en) * | 1996-10-31 | 2002-03-21 | Slk Foundation | Flavouring composition, production and use thereof |
| AU7126998A (en) * | 1997-04-16 | 1998-11-11 | Connaught Laboratories Inc. | Anti-influenza compositions supplemented with neuraminidase |
| WO2000035481A2 (en) | 1998-12-17 | 2000-06-22 | Connaught Laboratories Limited | Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation |
| AT407958B (de) * | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
| WO2001021151A1 (en) * | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
| US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
| ATE466085T1 (de) * | 2002-09-09 | 2010-05-15 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| AU2003284246A1 (en) | 2002-10-16 | 2004-05-04 | Samuel F. Hunter | Method for treatment of demyelinating central nervous system disease using gm-csf |
| WO2004066961A2 (en) * | 2003-01-20 | 2004-08-12 | St. Jude Children's Research Hospital | Use of sendai virus as a human parainfluenza vaccine |
| US7282353B2 (en) * | 2003-08-19 | 2007-10-16 | Academia Sinica | Protein isolation |
| AU2006206647C1 (en) | 2005-01-19 | 2011-01-20 | Vaxinnate Corporation | Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response |
| GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| EP1899470A4 (en) * | 2005-05-23 | 2009-07-29 | Vaxin Inc | SYSTEM FOR THE FAST MANUFACTURE OF REPLICATED COMPETENCE OF ADENOVIRUS-FREE RECOMBINANT ADENOVIRUS VECTORS WITH HIGH TITER |
| WO2007057763A2 (en) * | 2005-11-18 | 2007-05-24 | Pulmonox Technologies Corporation | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
| TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
| US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
| ES2555544T3 (es) | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| EP2139908A4 (en) | 2007-03-12 | 2011-02-16 | Antigen Express Inc | REMOVAL OF PROTEIN Li INVOLVED IN Li-RNAi CONSTRUCTIONS IN ANTICANCER IMMUNOTHERAPY |
| CN101307310B (zh) * | 2007-05-15 | 2012-08-08 | 康泰生医科技股份有限公司 | 具有提高产率及免疫原性的重组蛋白质表达系统 |
| EP2014279A1 (en) * | 2007-06-22 | 2009-01-14 | Pevion Biotech AG | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof |
| AU2009236585B2 (en) | 2008-04-18 | 2013-03-07 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
| WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
| KR20120129893A (ko) * | 2010-01-06 | 2012-11-28 | 백시네이트 코포레이션 | 고령자에 보호 면역을 제공하기 위한 방법 및 조성물 |
| CN114010776A (zh) | 2010-06-09 | 2022-02-08 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
| EA201300525A1 (ru) * | 2010-11-02 | 2014-02-28 | Гектор Мануэль Сепеда Лопес | Новые вакцины против пандемичного вируса гриппа a/h1n1 |
| EP2688588B1 (en) | 2011-03-21 | 2017-08-09 | Altimmune Inc. | Rapid and prolonged immunologic therapeutic |
| US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
| JP2019511255A (ja) | 2016-01-11 | 2019-04-25 | バーンダリ，インク． | マイクロニードル組成物およびそれを使用する方法 |
| CN105854009A (zh) * | 2016-05-03 | 2016-08-17 | 重庆三杰众鑫生物工程有限公司 | 应用番鸭肝炎病毒制备灭活疫苗的制备方法 |
| MX2023012554A (es) | 2018-12-12 | 2023-11-08 | Cambridge Tech Llc | Vacuna universal contra la gripe. |
| KR20240105413A (ko) | 2021-11-05 | 2024-07-05 | 사노피 | 헤마글루티닌과 뉴라미니다제를 포함하는 하이브리드 다가 인플루엔자 백신 및 이의 사용 방법 |
| IL312545A (en) | 2021-11-05 | 2024-07-01 | Sanofi Pasteur Inc | Multivalent Influenza Vaccines Including Hemagglutinin and Recombinant Neuraminidase and Methods of Using Them |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2667245B1 (fr) * | 1990-10-01 | 1992-11-06 | Rhone Merieux | Association vaccinale contre les pathogenes infectieux. |
| WO1994001133A1 (en) * | 1992-07-08 | 1994-01-20 | Schering Corporation | Use of gm-csf as a vaccine adjuvant |
-
1995
- 1995-04-28 US US08/430,971 patent/US5976552A/en not_active Expired - Lifetime
-
1996
- 1996-04-26 CN CNB961950706A patent/CN1141977C/zh not_active Expired - Fee Related
- 1996-04-26 DK DK96913234T patent/DK0830141T3/da active
- 1996-04-26 DE DE69628834T patent/DE69628834T2/de not_active Expired - Lifetime
- 1996-04-26 ES ES96913234T patent/ES2201184T3/es not_active Expired - Lifetime
- 1996-04-26 CA CA2222283A patent/CA2222283C/en not_active Expired - Fee Related
- 1996-04-26 AT AT96913234T patent/ATE243530T1/de active
- 1996-04-26 AU AU56312/96A patent/AU696690B2/en not_active Revoked
- 1996-04-26 PT PT96913234T patent/PT830141E/pt unknown
- 1996-04-26 EP EP96913234A patent/EP0830141B1/en not_active Expired - Lifetime
- 1996-04-26 WO PCT/US1996/005904 patent/WO1996033738A1/en not_active Ceased
-
1999
- 1999-01-22 US US09/235,901 patent/US20020071848A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0830141A1 (en) | 1998-03-25 |
| EP0830141B1 (en) | 2003-06-25 |
| DE69628834T2 (de) | 2004-05-06 |
| US20020071848A1 (en) | 2002-06-13 |
| AU696690B2 (en) | 1998-09-17 |
| WO1996033738A1 (en) | 1996-10-31 |
| ATE243530T1 (de) | 2003-07-15 |
| CA2222283A1 (en) | 1996-10-31 |
| DE69628834D1 (de) | 2003-07-31 |
| CN1141977C (zh) | 2004-03-17 |
| CA2222283C (en) | 2015-02-03 |
| US5976552A (en) | 1999-11-02 |
| ES2201184T3 (es) | 2004-03-16 |
| AU5631296A (en) | 1996-11-18 |
| CN1189103A (zh) | 1998-07-29 |
| HK1013595A1 (en) | 1999-09-03 |
| PT830141E (pt) | 2003-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0830141T3 (da) | Forbedrede virusvacciner | |
| Hashigucci et al. | Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin | |
| EP0705109B2 (en) | Adjuvants for vaccines against respiratory syncytial virus | |
| AU2684792A (en) | Porcine reproductive respiratory syndrome vaccine and diagnostic | |
| FI905184A0 (fi) | Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3. | |
| Kodihalli et al. | A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection | |
| ATE295895T1 (de) | Genetischer impfstoff gegen den immunschwäche virus | |
| RU2000116260A (ru) | Вакцины с адъювантом ltb | |
| RU94042386A (ru) | Вакцина против гепатита, содержащая 3-0-дезацилированный монофосфорил-липида, применение антигена гепатита для получения препарата для лечения гепатита, способ лечения гепатита | |
| MX9702336A (es) | Composiciones de vacuna. | |
| EA200000528A1 (ru) | Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией | |
| MX9802285A (es) | Vacunas y glicoproteinas de virus de parainfluenza. | |
| ES2127294T3 (es) | Vacunas del virus de la inmunodeficiencia anti-felino (fiv). | |
| ATE101200T1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
| Downie | Neuraminidase-and hemagglutinin-inhibiting antibodies in serum and nasal secretions of volunteers immunized with attenuated and inactivated influenza B/Eng/13/65 virus vaccines | |
| AU3887695A (en) | Interleukin-12 as an adjuvant for paramyxoviridae vaccines | |
| IE32140B1 (en) | Vaccines | |
| DE69720024D1 (de) | Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten | |
| Liashenko et al. | Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measles vaccine L-16 | |
| BR9909076A (pt) | Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b | |
| WO2001083528A3 (en) | Nucleic acid immunization | |
| PT100460A (pt) | Partiiculas derivadas de virus de herpes e vacinas que as contem | |
| Trudel et al. | Efficient intranasal vaccination of mice against human respiratory syncytial virus with an experimental iscoms subunit vaccine | |
| Teokhorova et al. | Clinical and immunological studies in the use of an experimental lot of hepatitis B vaccine. | |
| Reddy et al. | Efficacy of a combined live attenuated canine distemper and inactivated rabies vaccine in dogs |